The dose of total body irradiation (TBI), and GvHD prophilaxis have a crucial role on relapse risk and survival after BMT for leukaemia.
Frassoni
F
F
Centro Trapianti Midollo Osseo, Divisione Ematologia, Genova, Italy.
Bacigalupo
A
A
Sessarego
M
M
Gualandi
F
F
Lamparelli
T
T
Van Lint
M T
MT
Occhini
D
D
Corvò
R
R
Scarpati
D
D
Vitale
V
V
D016026:Bone Marrow Transplantation / Q000379:methods* / Q000401:mortality; D003520:Cyclophosphamide / Q000627:therapeutic use; D003524:Cyclosporins / Q000008:administration & dosage / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D007558:Italy / Q000453:epidemiology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000601:surgery*; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000601:surgery*; D008727:Methotrexate / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D012307:Risk Factors; D015996:Survival Rate; D014916:Whole-Body Irradiation / Q000401:mortality
D003524:Cyclosporins; D003520:Cyclophosphamide; D008727:Methotrexate